Overview
Are We There Yet? Strategies to Employ JAK Inhibitors in T2T for RA
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are your RA patients satisfied? A 2019 survey by Radawski et al suggests otherwise: three out of four RA patients are not satisfied with their treatment, including bDMARDs. This expert live recording from a virtual lecture series updates clinicians on how to select the right target for each patient, how often to assess whether the target has been achieved, and how to optimize selection of each subsequent therapy, including when to introduce JAK inhibitors. This activity also includes downloadable slides from the virtual lecture series.
This activity is intended for rheumatologists, internal medicine physicians, nurses, and other allied healthcare professionals interested in treatment advances for patients with rheumatoid arthritis (RA).
An expert faculty member will discuss practical application of the latest JAK inhibitor clinical trial data as well as strategies to identify patients eligible for these newer agents as part of T2T care plans. Video-based patient testimonials will complement and introduce the clinical commentary discussion and topics such as approved and emerging JAK inhibitors, including efficacy and safety profiles.
*Update February 2021: New safety data released on tofacitinib. Press release here.
As a result of participating in this activity, learners will be able to:
- Interpret clinical trial efficacy, safety, and tolerability of JAK inhibitors for the treatment of RA
- Identify patients with RA who may be candidates for a JAK inhibitor
- Formulate treat-to-target strategies that account for disease activity, treatment response, and patient-specific factors
- Patient Journey #1: Diagnostic and Treatment Journey
- JAK Inhibition: A Rational and Effective Approach to RA
- Patient Journey #2: JAK Inhibitor Experiences
- Patient Journey #3: Shared Decision-making and Barriers to Optimal RA Care
- Treat-to-Target and Personalized Management Strategies
- JAK Inhibition: A Rational and Effective Approach to RA
- Patient Journey #2: JAK Inhibitor Experiences
- Patient Journey #3: Shared Decision-making and Barriers to Optimal RA Care
- Treat-to-Target and Personalized Management Strategies
Supported by an educational grant from Gilead Sciences, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Department of Medicine
Weill Medical College of Cornell University
Attending Physician
Department of Rheumatology/Medicine
Co-Director, Clinic for Inflammatory Arthritis and Biologic Therapy
Hospital for Special Surgery and New York Presbyterian Hospital
New York, NY
Professor of Medicine, Healthcare Policy and Research
Department of Medicine
Weill Medical College of Cornell University
Attending Physician
Department of Rheumatology/Medicine
Co-Director, Clinic for Inflammatory Arthritis and Biologic Therapy
Hospital for Special Surgery and New York Presbyterian Hospital
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Consultant: AbbVie Inc., Gilead Sciences, Inc., Eli Lilly and Company, Pfizer Inc.
Speakers’ Bureau: AbbVie Inc., Eli Lilly and Company, Pfizer Inc.
Shareholder: AbbVie Inc., Pfizer Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Filgotinib JAK inhibition for RA
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements